Creative Biolabs possesses unchallenged experience in antibody development and recombinant protein synthesis. We offer a full set of bispecific antibody (BsAb) services, including design, engineering, manufacture and analysis of BsAbs for immunology application.
The immune system is crucial for human health as it defends the body from various ‘foreign’ intrusions and malfunctioning self-cells. The immune system helps to maintain human health yet sometimes malfunctioning or excessive immune responses also give rise to tissue damage/destruction, altered organ growth, and altered organ function. There are various immunological disorders, including chronic inflammation, autoimmune disease, hypersensitivity, immune deficiency, and transplant rejection. BsAbs are capable of receptor signaling interference and can be applied to immunology.
Figure 1. Therapeutic BsAbs interference with receptor signaling binding cell surface receptors or bind to their cognate ligands. (Roland E. Kontermann, 2015)
Signaling networks take control of every aspect of intracellular and intercellular biological functions and behaviors, from regulated catabolism and metabolism to programmed cell proliferation or death, and eventually to overall human health. In many cases, by supplementation of the missing signal factors or blockage of the malfunctioning signaling pathways, symptom and the progression of the disease can be controlled. Comparing to previous monospecific antibody drugs, BsAbs can interfere with two (or more) receptors or ligands in one or two pathways simultaneously. This character of BsAb reduces the possibility of escaping mechanisms and increases drug efficacy. Excessive or malfunctioning (such as self-targeting) inflammatory reactions lead to lots of disorders and inflammatory and autoimmune diseases. Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Behcet's disease, psoriasis, inflammatory bowel disease, allergy, and cardiovascular diseases are some well-known examples.
Several BsAbs are designed to block pro-inflammatory signaling pathways and have been pushed into clinical trials. ABT981 (from Abbott Company) is a DVD-Ig BsAb which is designed to interfere with receptor ligand IL-1a and IL-1b, two validated targets in rheumatoid arthritis. ALX0761 (from Merck Serono–Ablynx Company) binds the signaling ligands IL-17F and IL-17A and is a bispecific nanobody. Bi-Mab (from Zymogenetics) is a scFv-Fc BsAb which targets the IL17 and IL23 signaling.
Figure 2. Examples of various forms of the BsAbs designed for (A) blockage of pro-inflammatory pathways and (B) other receptor signaling interference (Kontermann, R. E., 2015)
The superior BsAb production platforms and brilliant research team in Creative Biolabs guarantee our customers high-quality BsAbs. Customers can enjoy time and budget saving BsAb services.
Kontermann, R. E.; Brinkmann, U. Bispecific antibodies. Drug discovery today. 2015, 20(7): 838-847.